Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.
Guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE) prophylaxis have been developed for patients undergoing total hip arthroplasty (THA). Studies suggest that risk for developing these complications may exist for as long as 3 months following surgery. Cost-effectiveness analyses were performed on three pharmacoprophylaxis regimens administered over a 30-day period using literature-reported values for incidences of DVT and PE in patients postdischarge following THA. A cost savings of $21,466.89 will occur for each thromboembolic event avoided if low-dose warfarin daily is used routinely compared to enoxaparin 40 mg daily. Additionally, a cost savings of $18,618.10 is experienced if enoxaparin 40 mg daily for 4 days plus low-dose warfarin daily is administered versus enoxaparin 40 mg daily. Clinicians may choose to continue prophylaxis postdischarge with enoxaparin 40 mg daily for 4 days in combination with warfarin for 30 days in these patients until results of more definitive studies become available.
Wade
W E
WE
College of Pharmacy, University of Georgia, Athens 30602, USA.
Hawkins
D W
DW
D000328:Adult; D000553:Ambulatory Care / Q000191:economics*; D000925:Anticoagulants / Q000008:administration & dosage / Q000191:economics*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects* / Q000379:methods; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017984:Enoxaparin / Q000008:administration & dosage / Q000191:economics*; D005260:Female; D005845:Georgia; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D011379:Prognosis; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin